Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase

References

• ADAMS, J. L., BOEHM, J. C., KASSIS, S., GORYCKI, P. D., WEBB, E. F., HALL, R., SORENSON, M., LEE, J. C., AYRTON, A., GRISWOLD, D. E. and GALLAGHER, T. F., 1998, Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorganic Medicine and Chemistry Letters, 8, 3111–3116.
   PubMed Web of Science ®Google Scholar
• BADGER, A. M., BRADBEER, J. N., VOTTA, B., LEE, J. C., ADAMS, J. L. and GRISWOLD D. E., 1996, Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. Journal of Pharmacology and Experimental Therapeutics, 279, 1453–1461.
   Google Scholar
• BARANCIK, M., HTUN, P., STROHM, C., KILIAN, S. and SCHAPER, W., 2000, Inhibition of the cardiac p38-MAPK pathway by 5B203580 delays ischemic cell death. Journal of Cardiovascular Pharmacology, 35, 474–483.
   PubMed Web of Science ®Google Scholar
• BEHRENS, M. M., STRASSER, U., KOH, J.Y., GWAG, B. J. and CHOI, D. W., 1999, Prevention of neuronal apoptosis by phorbol ester-induced activation of protein kinase C: Blockade of p38 mitogen-activated protein kinase. Neuroscience, 94, 917–927.
   PubMed Web of Science ®Google Scholar
• BENET, L. Z., MITCHELL, J. R. and SHEINER, L. B., 1990, General principles: introduction. In Goodman and Gilman's The Pharmacological Basis of Therapeutics (New York: Pergamon).
   Google Scholar
• BOLIDINOT, F. D. and Jusito, W. J., 1984, Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. Journal of Pharmaceutical Sciences, 73, 774–780.
   PubMed Web of Science ®Google Scholar
• CHAKRAVORTTY, D., KATO, Y., KOIDE, N., SUGIYAMA, T., KAWAI, M., FUKADA, M., YOSHIDA, T. and YOKOCHI, T., 2000, Extracellular matrix components prevent lipopolysaccharide-induced bovine arterial endothelial cell injury by inhibiting p38 mitogen-activated protein kinase. Thrombosis Research, 98, 187-1 93.
   Google Scholar
• COBB, M. H., 1999, MAP kinase pathways. Progress in Biophysics and Molecular Biology, 71, 479-500. DAVIES, B. and MORRIS, T., 1993, Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 10, 1093–1095.
   Google Scholar
• GABRIELSSON, J. and WEINER, D., 1997, Pharmacokinetk and Pharmacodynamk Data Analysis: Concepts and Applications (Stockholm: Apotekarsocieteten).
   Google Scholar
• GALLAGHER, T. F., FIER-THOMPSON, S. M., GARIGIPATI, R. S., SORENSON, M. E., SMIETANA, J. M., LEE, D., BENDER, P. E., LEE, J. C., LAYDON, J. T., GRISWOLD, D. E., CHABOT-FLETCHER, M. C., BRETON, J. C. and ADAMS, J. L., 1995, 2,4,5-triarylimidazole inhibitors of IL-1 biosynthesis. Bioorganic Medicine and Chemistry Letters, 5, 1171–1176.
   Google Scholar
• HOWARD, M. 0., NEWTON, J. F., KOHANE, D. J., YODIS, L. P., SAVERINO, C. M., QUALLS, C. W., JR and SCHWARTZ, L. W., 1 990, In vitro metabolism of the novel antiinflammatory agent 6-(4-fluorophenyl) -5 -(4-pyridy1)-2,3-dihydroimidazo-{2,1 -b}-thiazole. Drug Metabolism and Disposi-tion, 18, 607–612.
   Google Scholar
• JovEux, M., BOUMENDJEL, A., CARROLL, R., RIBOUT, C., GODIN-RIBOUT, D. and YELLON, D. M., 2000, SB 203580, a mitogen-activated protein kinase inhibitor, abolishes resistance to myocardial infarction induced by heat stress. Cardiovascular and Drugs Therapy, 14, 337–343.
   PubMed Web of Science ®Google Scholar
• LIANG, F., Lu, S. and GARDNER, D. G., 2000, Endothelin-dependent and -independent components of strain-activated brain natriuretic peptide gene transcription require extracellular signal regulated kinase and p38 mitogen-activated protein kinase. Hypertension, 35, 188–192.
   PubMed Web of Science ®Google Scholar
• MA, X. L., KUMAR, S., GAO, F., LOUDEN, C. S., LOPEZ, B. L., CHRISTOPHER, T. A., WANG, C., LEE, J. C., FEUERSTEIN, G. Z. and YUE, T.L., 1999, Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation, 99, 1685–1691.
   PubMed Web of Science ®Google Scholar
• NEWTON, J. F., YODIS, L. P., KEOHANE, D., ECKARDT, R., DEWEY, R., DENT, J. and Mico, B., 1989, Pharmacokinetics and metabolism of SK&F 86002 in male and female Sprague-Dawley rats. Drug Metabolism and Disposition, 17, 174–179.
   PubMed Web of Science ®Google Scholar
• PACIFICI, G. M. and VIANI, A., 1992, Methods of determining plasma and tissue binding of drugs. Clinical Pharmacokinetics, 23, 449–468.
   PubMed Web of Science ®Google Scholar
• ROWLAND, M. and TOZER, T. N. (eds), 1995, Distribution. In Clinical Pharmacokinetics (Philadelphia: Lippincott Williams & Wilkins), pp. 137–155.
   Google Scholar
• STEIN, B. and ANDERSON, D., 1996, The MAP kinase family: New `MAPs' for signal transduction pathways and novel targets for drug discovery. Annual Reports in Medicine and Chemistry, 31, 289–298.
   Web of Science ®Google Scholar
• WARD, K. W., GRIFFITHS, R., LEVY, M. A. and SMITH, B. R., 2000, Evaluation of the use of accelerated infusions for the determination of pharmacokinetic linearity. Journal of Pharmacology and Experimental Therapeutics, 293, 468–479.
   PubMed Web of Science ®Google Scholar
• Yu, R., MANDELKAR, S., LEI, W., FAHL, W. E., TAN, T.H. and KONG, A.-N. T., 2000, p38 mitogen-activated protein kinase negatively regulates the induction of Phase II drug-metabolizing enzymes that detoxify carcinogens. Journal of Biological Chemistry, 275, 2322–2327.
   Google Scholar
• YUE, T.L., WANG, C., Gu, J.L., MA, X.L., KUMAR, S., LEE, J. C., FEUERSTEIN, G. Z., THOMAS, H., MALEE, B. and OHLSTEIN, E. H., 2000, Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circulation Research, 86, 629–699.
   Web of Science ®Google Scholar